Lennart Hansson

Biography

Board member of InDexPharmaceuticals Holding AB since 2016 and board member of InDex Pharmaceuticals AB and InDex Diagnostics AB since 2011.  Hansson is board member of Ignitus AB, Calliditas Therapeutics AB, Sixera Pharma AB and Medtentia International Ltd. as well as Cinclus Pharma AG.  Hansson was board member of Malmö Industrifinans AB until 2015, CMC Contrast Aktiebolag until 2011, Uminova Invest AB until 2015, Lund University Bioscience AB until 2012, OxThera AB until 2012 and Medtentia AB until 2011 (and later deputy board member until 2012). Ha was also deputy board member of Airsonett Holding AB until 2015.  Hansson has been engaged in the Life Science unit at Industrifonden since 2008. Previously he has more than 20 years’ experience from pharma and biotech industry in executive position at KabiGen, Symbicom AB, AstraZeneca AB and BioVitrum AB and as CEO for Arexis AB. Between 2006 and 2008 he worked for Karolinska Development. He has a PhD from Umeå University.

Research Interest

pharma and biotech industry